Publication date: October 2019Source: European Journal of Cancer, Volume 120Author(s): Peter Hohenberger, Sylvie Bonvalot, Frits van Coevorden, Pjotr Rutkowski, Eberhard Stoeckle, Christine Olungu, Saskia Litiere, Eva Wardelmann, Alessandro Gronchi, Paolo CasaliAbstractBackgroundEORTC (European Organisation of Research and Treatment of Cancer) 62024 is a phase III randomised trial evaluating adjuvant imatinib in patients with gastrointestinal stromal tumours (GISTs) and no evidence of residual disease...
Sun Sep 01, 2019 16:23
Publication date: October 2019Source: European Journal of Cancer, Volume 120Author(s): Pauline Corbaux, Mévidette El-Madani, Michel Tod, Julien Péron, Denis Maillet, Jonathan Lopez, Gilles Freyer, Benoit YouAbstractBackgroundDetermining the optimal biological dose (OBD) has been described as an alternative strategy to the maximum tolerated doses (MTDs) for identifying the recommended phase II trial doses (RP2Ds) of phase I anti-cancer therapies. However, the clinical relevance is still unknown. An...
Sun Sep 01, 2019 16:23
Publication date: October 2019Source: European Journal of Cancer, Volume 120Author(s): Heejung Chae, Deokhoon Kim, Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Shin Hwang, Ki-Hun Kim, Gi-Won Song, Chul Soo Ahn, Jae Hoon Lee, Dae Wook Hwang, Song Cheol Kim, Se Jin Jang, Seung-Mo Hong, Tae Won Kim, Baek-Yeol RyooAbstractPurposeIn biliary tract cancer (BTC), standard chemotherapy has limited benefit and no molecular targeted agents have been approved....
Sat Aug 31, 2019 12:54
Publication date: Available online 31 August 2019Source: European Journal of Surgical OncologyAuthor(s): M. Vos, W.C. Boeve, T.M. van Ginhoven, S. Sleijfer, C. Verhoef, D.J. GrünhagenAbstractBackgroundTumor location as prognostic factor for patients with liposarcoma (LPS) has been studied modestly with varying outcomes. The aim was to establish the impact of tumor location on recurrence and survival of LPS patients.MethodsA retrospective database of patients treated for LPS until December 2017 was...
Sat Aug 31, 2019 14:39
Publication date: Available online 31 August 2019Source: European Journal of Surgical OncologyAuthor(s): Su Mi Kim, Ji Yeong An, Sun-ju Byeon, Jeeyun Lee, Kyoung-Mee Kim, Min-Gew Choi, Jun Ho Lee, Tae Sung Sohn, Jae Moon Bae, Sung KimAbstractObjectiveThe predictive value of mismatch repair protein deficiency (MMRD) for chemoradiotherapeutic outcome has rarely been reported in gastric cancer. This study investigated the clinical significance of MMRD as a prognostic factor for tumor recurrence, and...
Sat Aug 31, 2019 14:39
Publication date: Available online 30 August 2019Source: European Journal of Surgical OncologyAuthor(s): Maximino Redondo, Teresa Téllez
Sat Aug 31, 2019 14:39
Publication date: Available online 29 August 2019Source: European Journal of Surgical OncologyAuthor(s): Martin Graversen, Sönke Detlefsen, Signe Bremholm Ellebaek, Claus Fristrup, Per Pfeiffer, Michael B. MortensenAbstractIntroductionElectrostatic precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC) has shown superior penetration depth and tissue uptake compared to standard PIPAC. We investigated the feasibility and objective tumor response to ePIPAC with 1 min of precipitation...
Fri Aug 30, 2019 14:28
Future Oncology, Volume 15, Issue 25, Page 2887-2889, September 2019.
Fri Aug 30, 2019 12:16
Related ArticlesTreatment sequencing in oncology: balancing clinical trial and real-world evidence. Future Oncol. 2019 Sep;15(25):2887-2889 Authors: Caffo O PMID: 31469005 [PubMed - in process]
Sat Aug 31, 2019 14:21
Related ArticlesAbemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol. 2019 Aug 29;: Authors: Lee KA, Shepherd ST, Johnston SR Abstract CDK 4/6 inhibitors have given patients with estrogen receptor (ER)-positive/HER2-negative (ER+/HER2ࢤ) advanced metastatic breast cancer important new therapeutic options. Abemaciclib is different to the other two licensed and approved CDK...
Fri Aug 30, 2019 15:29
Abstract There is experimental and observational evidence that the cells of the leukemic clone in acute myeloid leukemia (AML) have different phenotypes even though they share the same somatic mutations. The organization of the malignant clone in AML has many similarities to normal hematopoiesis, with leukemia stem cells (LSCs) that sustain leukemia and give rise to more differentiated cells. LSCs, similar to normal hematopoietic stem cells (HSCs), are those cells that are able to give rise to a...
Sat Aug 31, 2019 11:03
ABSTRACT Tenosynovial giant cell tumors (TGCTs) are characterized by rearrangements of CSF1, thought to drive overexpression of macrophage colony‐stimulating factor (CSF1), thereby promoting tumor growth and recruitment of non‐neoplastic mononuclear and multinucleated inflammatory cells. While fusions to collagen promoters have been described, the mechanism of CSF1 overexpression has been unclear in a majority of cases. Two cohorts of TGCT were investigated for CSF1 rearrangements using fluorescence...
Fri Aug 30, 2019 18:33
Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify gender‐based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO)...
Sat Aug 31, 2019 17:32
Gastric cancer remains a leading cause of cancer‐related mortality. Identifying dietary and other modifiable disease determinants has important implications for risk attenuation in susceptible individuals. Our primary aim was to estimate the association between dietary and supplemental intakes of calcium and magnesium and the risk of incident gastric cancer. We conducted a prospective cohort analysis of the NIH‐AARP Diet and Health Study. We used Cox proportional hazard modeling to estimate the association...
Sat Aug 31, 2019 17:29
Kirsten rat sarcoma (KRAS) mutant cancers, which constitute the vast majority of pancreatic tumors, are characterized by their resistance to established therapies and high mortality rates. Here, we developed a novel and extremely effective combinational therapeutic approach to target KRAS mutant tumors through the generation of a cytotoxic oxidative stress. At high concentrations, Vitamin C (VC) is known to provoke oxidative stress and selectively kill KRAS mutant cancer cells, although its effects...
Sat Aug 31, 2019 17:28
In metastatic colorectal cancer (mCRC), circulating tumor DNA (ctDNA) monitoring can be used to genotype tumors and track clonal evolution. We investigated the clearance of RAS mutated clones under chemotherapy pressure by ctDNA analysis in patients with a RAS mutated mCRC. Patients with a RAS mutated tumor included in the prospective PLACOL study, were monitored for ctDNA. Analyzes were based on optimized targeted next generation sequencing and/or droplet‐based digital PCR (ddPCR). For plasma samples...
Sat Aug 31, 2019 17:22
Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)‐associated and has the highest incidence and mortality rates mostly in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established...
Fri Aug 30, 2019 18:43
Methylation of the promoter of the BRCA1 gene in DNA derived from peripheral blood cells is a possible risk factor for breast cancer. It is not clear if this association is restricted to certain types of breast cancer or is a general phenomenon. We evaluated BRCA1 methylation status in peripheral blood cells from 942 breast cancer patients and from 500 controls. We also assessed methylation status in 262 paraffin‐embedded breast cancer tissues. Methylation status was assessed using methylation‐sensitive...
Fri Aug 30, 2019 18:39
Many long intergenic noncoding RNAs (lincRNAs) serve as cancer biomarkers for diagnosis or prognostication. To understand the role of lincRNAs in the rare neuroendocrine tumors pheochromocytoma and paraganglioma (PCPG), we performed first time in‐depth characterization of lincRNA expression profiles and correlated findings to clinical outcomes of the disease. RNA‐Seq data from patients with PCPGs and 17 other tumor types from The Cancer Genome Atlas and other published sources were obtained. Differential...
Fri Aug 30, 2019 18:30
Women of African Ancestry have lower incidence of epithelial ovarian cancer (EOC) yet worse survival compared to women of European Ancestry. We conducted a genome‐wide association study (GWAS) in African ancestry women with 755 EOC cases, including 537 high‐grade serous ovarian carcinomas (HGSOC), and 1,235 controls. We identified four novel loci with suggestive evidence of association with EOC (P < 1x10−6), including rs4525119 (intronic to AKR1C3), rs7643459 (intronic to LOC101927394), rs4286604...
Fri Aug 30, 2019 18:29
Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by bindi...
Fri Aug 30, 2019 03:00
Ovarian carcinomas are the deadliest gynecological malignancies owing to their high rate of recurrence and high resistance to platinum-based chemotherapy. Recent studies have shown platinum-dependent enrichmen...
Fri Aug 30, 2019 03:00
Abstract Small nucleolar RNA host gene 1 (SNHG1) is critical in the progression of cancers. However, the mechanism by which SNHG1 regulates the progression of colorectal cancer (CRC) remains unclear. Expressions of SNHG1 and miR‐137 in CRC tissues and cell lines were evaluated by quantitative real‐time polymerase chain reaction. A luciferase reporter gene assay was conducted to investigate miR‐137 target. Additionally, RNA pull‐down assay was performed to explore the physical association between...
Fri Aug 30, 2019 12:45
Publication date: Available online 31 August 2019Source: Practical Radiation OncologyAuthor(s): Michael C. Dobelbower, Richard A. Popple, Douglas J. Minnich, Daniel A. Nader, Frank Zimmerman, Gerald E. Paris, Felix J.F. Herth, Daniela R. Gompelmann, Falk F. Roeder, Parag J. Parikh, Andrew M. McDonald
Sun Sep 01, 2019 17:53
Publication date: Available online 31 August 2019Source: Practical Radiation OncologyAuthor(s): Maria Lavin Cabanas, Chenyu Yan, Ronald J. Lalonde, Dwight E. Heron, M. Saiful HuqAbstractPurposeTo compare the doses calculated by AAA, Acuros dose-to-medium and Acuros dose-to-water for the lung patients treated at our institution and show that further investigation and clarification are needed about what dose specification should be used for NRG clinical trials.Methods and MaterialsTwenty-one lung patients...
Sat Aug 31, 2019 18:00
Fri Aug 30, 2019 21:24
Transforming growth factor beta 1 (TGF-β1) and platelet-derived growth factor (PDGF) are cytokines involved in fibrotic processes causing radiotherapy (RT)-induced cardiovascular changes. We aimed to investiga...
Fri Aug 30, 2019 03:00
Target localization in radiation therapy is affected by numerous sources of uncertainty. Despite measures to minimize the breathing motion, the treatment of hypofractionated liver radiation therapy is further ...
Fri Aug 30, 2019 03:00
Stereotactic body radiotherapy (SBRT) is an established treatment option in the management of patients with early-stage non-small cell lung cancer (NSCLC). Prospective studies have demonstrated that SBRT achieves high rates of local tumor control [1–3]. Compared to conventionally-fractionated radiotherapy (CFRT) for early stage NSCLC, SBRT is associated with equivalent tumor control, shortened treatment times, and decreased toxicity, with larger retrospective studies even suggesting a survival benefit...
Sat Aug 31, 2019 03:00
Cervical cancer is the fourth most frequent cancer in women, with an estimated 570,000 new cases in 2018, representing 6.6% of all female cancers worldwide. Cervical cancer still represents a significant burden for middle- and low-income countries [1]. Standard treatment for locally advanced (stage IB2-IVA) cervical cancer is concurrent chemoradiation.
Fri Aug 30, 2019 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου